Mineralys Therapeutics Advances Lorundrostat NDA Toward December 2026 FDA PDUFA Date

With a PDUFA target date of December 22, 2026, Mineralys Therapeutics is moving lorundrostat through active FDA NDA review for use in combination with existing antihypertensive agents, a timeline that puts commercial readiness decisions squarely on the critical path for supply chain and regulatory teams now.

The NDA, submitted following the Transform-HTN pivotal program, covers lorundrostat's use in uncontrolled or resistant hypertension via aldosterone suppression. The ongoing Transform-HTN open-label extension trial continues to generate long-term safety and efficacy data that may inform post-approval commitments. For QA and regulatory leads, the extension trial's active status signals that label negotiations and potential post-marketing study requirements remain live variables ahead of any approval action.

On the commercial infrastructure side, Mineralys reports that initial sales territories and priority geographies have been defined and engagement with hypertension specialists and payers is underway. For plant heads and supply planners, that geographic segmentation provides an early signal on demand concentration and the distribution network scope that will need to align with any approved product launch.

Mineralys also appointed James J. "Terry" Ferguson III, M.D. as Chief Medical Officer, effective August 10, 2026. Ferguson brings more than 35 years in cardiovascular medicine and drug development, including roles as Cardiovascular Therapeutic Area Head at Amgen and leadership positions at AstraZeneca and The Medicines Company. His predecessor, David Rodman, M.D., who led lorundrostat's development from proof-of-concept through NDA filing, transitions to a full-time Strategic Advisor role. The leadership continuity structure is notable given the proximity to a potential approval action and the medical affairs build-out that typically accelerates post-PDUFA.

Separately, Mineralys repurchased the Tanabe royalty obligation, a move the company characterizes as improving the long-term economics of lorundrostat. The financial restructuring, combined with a balance sheet strengthening initiative, reduces downstream revenue-sharing exposure if the product reaches market.

The FDA's review clock on the lorundrostat NDA makes December 22, 2026 the next definitive checkpoint for the resistant hypertension treatment landscape.

Source: Mineralys Therapeutics, Inc. via GlobeNewswire, August 11, 2026. Conference call held same day at 4:30 p.m. ET.